Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Illumina (ILMN)

Illumina Names Eric Green Chief Medical Officer; Chief Commercial Officer Cunningham Resigns

Neutral Impact 4 of 5 leadership Written later

Illumina said it appointed Eric D. Green, M.D., Ph.D., former director of the National Human Genome Research Institute, as Chief Medical Officer effective February 2, 2026. Chief Commercial Officer Everett Cunningham is resigning effective January 16, 2026, and CEO Jacob Thaysen will serve as interim chief commercial officer until a successor is named.

Key points

  • Eric D. Green, M.D., Ph.D., appointed Chief Medical Officer, effective February 2, 2026; reports to the CEO
  • Green served as NHGRI Director from 2009 to 2025 and spent more than three decades at the National Institutes of Health
  • Everett Cunningham resigns as Chief Commercial Officer effective January 16, 2026; he has been appointed CEO of a life science tools company
  • CEO Jacob Thaysen will act as interim chief commercial officer until a permanent successor is named

The filing

CompanyIllumina (ILMN)
Form8-K, current report
Filed with the SECJan 8, 2026, 4:39 PM ET
Accession number0001110803-26-000006

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 08, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.